Therapeutic strategies focus on enhancing the immune-activating properties of IL-2, IL-7, IL-12, and IL-15, while also suppressing the pro-inflammatory and tumor-promoting cytokines, such as TNF-α, IL-1β, and IL-6. This evidence concerns the gene IL2 and neoplasm.